【摘要】 目的观察地特胰岛素（Det）对血糖控制不佳的2型糖尿病患者空腹血糖（FBG）变异的影响。方法 60例血糖控制不佳的2型糖尿病患者随机分为两组,每组30例。在原有治疗方案的基础上,Det组和精蛋白生物合成入胰岛素（NPH）组分别睡前加用Det或NPH,皮下注射,每日一次,疗程均为12周。检测治疗前后FBG、糖化血红蛋白(HbA_1c)、空腹血糖变异系数（CV-FBG）等指标,并观察低血糖事件。结果治疗12周后,两组FBG及HbA_1c均较治疗前明显降低（P<0.05）,组间无显著差异（P>0.05）。Det组CV-FBG为12.49±2.47,明显低于NPH组（14.95±3.31,P<0.05）。Det组患者体重增加（1.25±0.75）kg,体重增加幅度低于NPH组[（1.98±0.84）kg,P<0.05]。Det组低血糖发生率低于NPH组（7%vs.17%,P<0.05）。两组均未出现严重不良反应。结论 Det在控制血糖方面疗效与NPH相当,且能减少FBG变异,降低低血糖风险并减少体重增加。更多还原

【Abstract】 AIM To investigate effect of insulin detemir（Det） on coefficient of variation（CV） of fasting blood glucose（FBG） in patients with type 2 diabetes.METHODS A total of 60 ptients with type 2diabetes inadequately controlled were randomized into once-daily Det（n = 30） versus isophane protamine biosynthetic human insulin（NPH,n = 30） for 12 weeks.Outcome measures included FBG,glycosylated hemoglobin A_1c(HbA_1c),CV-FBG,body weight and events of the hypoglycemia.RESULTS After 12 weeks of the treatment,FBG and HbA_1c decreased significantly in both groups（P < 0.05）.There was no statistical significance in FBG and HbA_1c between the two groups（P > 0.05）.The CV-FBG was lower in the Det group than that in the NPH group（12.49±2.47 vs.14.95±3.31,P < 0.05）.The mean weight gain and events of hypoglycemia were significantly lower in the Det group than those in the NPH group（（1.25±0.75） kg vs.（1.98±0.84） kg,7%vs.17%,P<0.05）.No severe adverse reaction occurred in the two groups.CONCLUSION Insulin detemir is as effective as NPH in glycemic control,and with reduction in CV-FBG,hypoglycaemia and weight gain.更多还原